HOME >> BIOLOGY >> NEWS
Can The Economic Promise Of Drug Discovery Continue To Preserve The Suriname Forest?

as antifungal agents. In another example, graduate student John Berger has been able to enhance the anticancer activity of a new compound by synthesizing analogs, reports Kingston. "Now we're looking for others with more activity from which we can make analogs."

Meanwhile, Bristol-Myers Squibb has put more than 3,000 extracts through 32 screens each in six different therapeutic areas, with the result that one promising compound is continuing to be tested.

While looking for potential pharmaceutical products, project scientists conduct ethnobotanical and random botanical collections. Conservation International (CI) researchers collect plants that the shamans use to treat disease and injury. Such ethnobotanical collection is time consuming. The scientists must gain the shamans' trust to be able to go with them to collect plants. Meanwhile, researchers from the Missouri Botanical Garden (MBG) collect plants of interest at random and end up collecting more plants.

"So which collection strategy is the most productive?" the group wondered. The best way to test plants' activity, says Kingston, is to test it against its intended application. "If you have a plant that the shamans say promotes wound healing, you test it for that benefit. But we have not done that because we don't have tests that mimic whole-body responses."

Pharmaceutical companies are interested in the fundamental biochemistry of disease and have highly specific biochemical assays that they believe provide targets for novel compounds.

"We said to ourselves, 'These plants have been picked out over centuries by the shamans, so one would expect them to be more active than plants collected at random.' So we decided to compare the activity of extracts from plants collected by CI and the Missouri Botanical Garden," Kingston says.

Using yeast-based assays, the Virginia Tech researchers found there was a slight benefit to the ethnobotanical app
'"/>

Contact: David G.I. Kingston
dkingston@vt.edu
(540) 231-6570
Virginia Tech
31-Mar-1998


Page: 1 2 3 4

Related biology news :

1. Economic costs of extreme weather, state by state
2. Economic realities depleting arsenal of antiparasitic drugs
3. Economic model to aid alligator farmers
4. Multi Drug Resistant-TB: Russian Economic Collapse Will Lead To Global Spread Of "Ebola With Wings"
5. Good Ergonomics Is Good Economics
6. Penn State Eries Sea Grant To Focus On Ecology, Economic Development
7. New Gene Holds Promise For Controlling Crohns And Other Inflammatory Diseases
8. Continuing Research On Knee Surgery For Horses At Colorado State University Holds Promise Of Helping Humans With Osteoarthritis
9. New Protein-Like Polymer Shows Promise For Blood Vessel Replacement
10. Multicomponent Malaria Vaccine Shows Promise in Laboratory Tests
11. UD Valentine Science: Cell "Dating" Habits May Promise Healthier Hearts

Post Your Comments:
(Date:7/23/2014)... Chrysomya megacephala is commonly found in dead bodies ... time of death, referred to as the post mortem ... C. megacephala from Tamil Nadu is provided for ... characterization through generation of DNA barcoding. This study, significant ... Biodiversity Data Journal . , Chrysomya megacephala ...
(Date:7/23/2014)... New Rochelle, NY -- The potential for clinical ... for transplant-based therapeutic strategies has previously been hindered ... the development of tumors. The ability to use ... for the treatment of heart disease, specifically acute ... Stem Cells and Development , a peer-reviewed ...
(Date:7/23/2014)... MINNETONKA, Minn. , July 23, 2014 /PRNewswire/ ... technology company specializing in clinical study management systems, ... West , a proven life sciences industry executive ... named Chief Operating Officer (COO).  Clareece will be ... and sales growth, operational efficiency and quality product/service ...
Breaking Biology News(10 mins):Dead body feeding larvae useful in forensic investigations 2MedNet Appoints Clareece West As Chief Operating Officer 2
(Date:7/23/2014)... July 23, 2014 ... of Trendlines Agtech , announced it has ... Israel,s leading agricultural thermoplastics applications companies. ... Valentis,s technology combines nanocrystalline cellulose (NCC), a biodegradable, ... additional nanoparticles to produce highly improved polymeric films. ...
(Date:7/23/2014)... regulated information -- UCB today announced an important advance ... topline results from the latest Phase 3 study ... evaluate the efficacy and safety of brivaracetam ... to placebo, as adjunctive treatment in adult focal ... despite treatment with one or two concomitant antiepileptic ...
(Date:7/23/2014)... 2014  Sofinnova Ventures, a Menlo Park ... of Sofinnova Venture Partners IX, L.P. at the hard ... initial fund target of $425 million. Sofinnova ... Consistent with recent funds, SVP IX will provide capital ... along with select investments in earlier stage opportunities. Investments ...
(Date:7/23/2014)... 2014 OncLive® is pleased to ... joined its Strategic Alliance Partnership program. , ... UNC Lineberger will have the opportunity to work ... its cutting-edge research initiatives, community-directed cancer prevention programs, ... work with OncLive to educate their peers by ...
Breaking Biology Technology:Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Sofinnova Raises $500 Million Biotech Venture Fund 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3
Cached News: